Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2021 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Return on Capital Employed of 28.43% for Q1 2026, down 2784.0% year-over-year from 1.06% in Q1 2025, and down 104.58% quarter-over-quarter from 13.9% in Q4 2025.
Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2021 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 28.43% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2784.0% year-over-year to 28.43%; the TTM figure through Mar 2026 stood at 28.43% (down 2784.0% YoY), while the FY2025 annual figure was 14.28%, up 2357.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 28.43%, down from 13.9% in the prior quarter.
- The five-year high for Return on Capital Employed was 4.47% in Q2 2025, with the low at 61.95% in Q4 2023.
- The 5-year median for Return on Capital Employed is 34.64% (2022), against an average of 32.69%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed surged 5843 bps in 2025, then plunged 2784 bps in 2026.
- Monte Rosa Therapeutics' Return on Capital Employed stood at 34.64% in 2022, then tumbled by 79 bps to 61.95% in 2023, then soared by 40 bps to 36.88% in 2024, then soared by 62 bps to 13.9% in 2025, then plunged by 105 bps to 28.43% in 2026.
- Business Quant data shows GLUE's Return on Capital Employed at 28.43% in Q1 2026, 13.9% in Q4 2025, and 2.44% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | -27.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.80% |
| Mar 31, 2026 | -28.43% |
| Dec 31, 2025 | -13.90% |
| Sep 30, 2025 | 2.44% |
| Jun 30, 2025 | 4.47% |
| Mar 31, 2025 | -0.60% |
| Dec 31, 2024 | -36.88% |
| Sep 30, 2024 | -44.79% |
| Jun 30, 2024 | -52.99% |
| Mar 31, 2024 | -59.03% |
| Dec 31, 2023 | -61.95% |
| Sep 30, 2023 | -58.06% |
| Jun 30, 2023 | -48.17% |
| Mar 31, 2023 | -40.09% |
| Dec 31, 2022 | -34.64% |
| Sep 30, 2022 | -30.42% |
| Jun 30, 2022 | -27.82% |
| Mar 31, 2022 | -24.93% |
| Dec 31, 2021 | -20.33% |
| Sep 30, 2021 | -16.89% |